1,2-Diazabicyclo<3,3,1>nonan | 28579-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1,2-Diazabicyclo<3,3,1>nonan
• 英文别名: 1,2-diaza-bicyclo[3.3.1]nonane；Diazabicyclo[3.3.1]nonane；1,2-diazabicyclo[3.3.1]nonane
• CAS: 28579-90-0
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: KTSZYXNHBVWNNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009053716A1

  公开（公告）日：2009-04-30

  This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  这项发明提供了一种化合物，其为式(Ia)或(Ib)的嘌呤类化合物：及其药学上可接受的盐，这些化合物是PI3K的抑制剂，并且对p110δ同工型具有选择性，p110δ是Ia类PI3激酶，优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱，如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
• [EN] NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES<br/>[FR] AMIDES DE DIAZABICYCLOALCANES SÉLECTIVES D'UN SOUS-TYPE DE RÉCEPTEUR D'ACÉTYLCHOLINE NICOTINIQUE
  申请人：TARGACEPT INC

  公开号：WO2009111550A1

  公开（公告）日：2009-09-11

  The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

  本发明涉及结合并调节神经元尼古丁型乙酰胆碱受体活性的以下式(I)化合物，以及制备这些化合物的方法，含有这些化合物的药物组合物，以及利用这些化合物治疗各种疾病和疾病的方法，包括与中枢神经系统（CNS）功能障碍相关的疾病。
• NOVEL COMPOUNDS 515
  申请人：Ducray Richard

  公开号：US20100105655A1

  公开（公告）日：2010-04-29

  There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  提供了化学式（I）的新型嘧啶衍生物或其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• Novel heteroaryl-diazabicycloalkanes
  申请人：——

  公开号：US20030004153A1

  公开（公告）日：2003-01-02

  The present invention relates to novel heteroaryl-diazabicycloalkanes which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的杂环烷基二氮杂双环戊烷，发现其为烟碱乙酰胆碱受体的胆碱能配体。由于其药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统相关的疾病或紊乱，与平滑肌收缩相关的疾病或紊乱，内分泌疾病或紊乱，神经退行性疾病或紊乱，炎症相关的疾病或紊乱，疼痛以及由于滥用化学物质终止而引起的戒断症状等多种疾病或紊乱具有用处。
• Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose
  申请人：MAKScientific, LLC

  公开号：US20220033393A1

  公开（公告）日：2022-02-03

  The present invention relates to novel compounds that can act as antidotes for treating “Acute Cannabinoid Overdose” produced by classical cannabinoids such as Δ 9 -tetrahydrocannabinol (THC) and several synthetic psychoactive cannabinoids (SPCs). The cannabis constituent THC exerts its psychotropic effects via CB1 receptor activation and SPCs mimic the effects of THC with higher potency and severe neurotoxicity. Compounds disclosed in this invention, their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, N-oxides, salts, solvates, hydrates, isotopic variations and their polymorphic forms can be therapeutically useful in an emergency setting for counteracting the intoxicating effects of acute THC ingestion and SPC overdose. Also, aspects of the invention are concerned with pyrazoles, imidazoles, triazoles, thiazoles, oxazoles, dihydropyrazoles, pyrrolidinones, azetidines, oxyazetidines and azaspiro[3.3]heptanes with unique pharmacokinetic and pharmacodynamic properties for treating “Acute Cannabinoid Overdose”.

  本发明涉及一种新型化合物，可以作为治疗由经典大麻素（如Δ9-四氢大麻酚（THC））和几种合成精神活性大麻素（SPCs）产生的“急性大麻素过量”的解毒剂。大麻成分THC通过CB1受体激活发挥其精神活性作用，而SPCs则模拟THC的效果，具有更高的效力和严重的神经毒性。本发明披露的化合物及其对映体、二对映体、几何异构体、拉克酸盐、互变异构体、转型异构体、异构异构体、代谢物、N-氧化物、盐、溶剂合物、水合物、同位素变体及其多态形式在急诊情况下可以在对抗急性THC摄入和SPC过量的中毒作用方面具有治疗用途。此外，本发明涉及吡唑烷、咪唑烷、三唑烷、噻唑烷、噁唑烷、二氢吡唑烷、吡咯烷酮、氮杂环丁烷、氧杂环丁烷和氮杂螺[3.3]庚烷等具有独特药代动力学性能的化合物，用于治疗“急性大麻素过量”。